Historically driven by agendas set by the field force rather than the needs of its customers, COVID-19 has presented the pharma industry with the perfect storm to shift from a push-oriented content strategy to one that is pull-driven, a panel of high-level executives said at a recent meeting.
Pharma Content Marketing – Is Customer King Yet?
COVID-19 The Perfect Storm For Change
With digital marketing initiatives becoming key to communication with health providers, COVID-19 has presented the perfect storm to place customers at the heart of content generation strategy in an industry long driven by its field force, feel executives who discussed challenges around content generation and appeal at a recent summit.

More from Business
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
More from Scrip
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.